A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Zindel, Sonja ^a,b   Stock, Stephanie ^a   Müller, Dirk ^a   Stollenwerk, Björn ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

'Clinical course of venous thromboembolism'; 'Cost effectiveness analysis'; 'Major orthopaedic surgery'; 'Thromboembolic prophylaxis'

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

ARTICLE; COST BENEFIT ANALYSIS; DECISION TREE; ECONOMICS; FACTUAL DATABASE; GERMANY; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; MULTICENTER STUDY (TOPIC); POSTOPERATIVE COMPLICATION; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DECISION TREES; ENOXAPARIN; GERMANY; HUMANS; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; NATIONAL HEALTH PROGRAMS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; VENOUS THROMBOEMBOLISM;

MLCS; MLOWN;

EID: 84863514625     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-192     Document Type: Article

References (42)

1. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, Chest 2008 133 6 Suppl 381S 453S 18574271 (Pubitemid 351894916)
2. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE Guidelines http://guidance.nice.org.uk/CG92
3. Venous thromboembolism (VTE) in Europe. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, et al. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007 98 4 756 764
4. S 3 Leitlinie. Prophylaxe der venösen Thromboembolie (VTE). 2009/2010 2010 http://www.awmf.org/uploads/tx-szleitlinien/003-001l-S3-VTE- Prophylaxe-2010.pdf
5. Low-molecular-weight heparin: is small beautiful? Salzman EW, N Engl J Med 1986 315 15 957 959 10.1056/NEJM198610093151509 3762596
6. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al. N Engl J Med 1992 326 15 975 982 10.1056/NEJM199204093261502 1545850
7. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Prandoni P, Lensing AW, Buller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW, Lancet 1992 339 8791 441 445 10.1016/0140-6736(92)91054-C 1346817
8. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Prandoni P, Siragusa S, Girolami B, Fabris F, Blood 2005 106 9 3049 3054 10.1182/blood-2005-03-0912 16030191 (Pubitemid 41565898)
9. Newer anticoagulants in 2009. Samama MM, Gerotziafas GT, J Thromb Thrombolysis 2010 29 1 92 104 10.1007/s11239-009-0392-5 19838770
10. Rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-has no clinically relevant interaction with naproxen. Kubitza D, Becka M, Mueck W, Zuehlsdorf M, Br J Clin Pharmacol 2007 63 4 469 476 10.1111/j.1365-2125.2006. 02776.x 17100983 (Pubitemid 46426627)
11. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, et al. N Engl J Med 2008 358 26 2765 2775 10.1056/NEJMoa0800374 18579811 (Pubitemid 351930851)
12. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, Lancet 2008 372 9632 31 39 10.1016/S0140-6736(08)60880-6 18582928
13. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, N Engl J Med 2008 358 26 2776 2786 10.1056/NEJMoa076016 18579812 (Pubitemid 351930852)
14. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, et al. Lancet 2009 373 9676 1673 1680 10.1016/S0140-6736(09)60734-0 19411100
15. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials. Ageno W, Expert Rev Cardiovasc Ther 2009 7 6 569 576 10.1586/erc.09.37 19505271
16. Institut für das Entgeldsystem im Krankenhaus, G-DRG-System 2012 http://www.g-drg.de/cms/G-DRG-System-2012
17. Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system? Schreyogg J, Tiemann O, Busse R, Health Care Manag Sci 2006 9 3 269 279 10.1007/s10729-006-9094-0 17016933 (Pubitemid 44198212)
18. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W, Arch Intern Med 1998 158 14 1525 1531 10.1001/archinte.158.14.1525 9679793 (Pubitemid 28340985)
19. Leitlinie der deutschen Gesellschaft für Angiologie. Diagnostik und Therapie der Venenthrombose und der Lungenembolie http://www.awmf.org/uploads/ tx-szleitlinien/065-002-S2-Diagnostik-und-Therapie-der-Venenthrombose-und-der- Lungenembolie-06-2010-06-2015.pdf
20. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. Quinlan DJ, Eikelboom JW, Dahl OE, Eriksson BI, Sidhu PS, Hirsh J, J Thromb Haemost 2007 5 7 1438 1443 10.1111/j.1538-7836.2007. 02571.x 17425687 (Pubitemid 46965372)
21. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. Oster G, Tuden RL, Colditz GA, JAMA 1987 257 2 203 208 10.1001/jama.1987.03390020069029 3098991 (Pubitemid 17207832)
22. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G, Arch Intern Med 1995 155 7 757 764 10.1001/archinte.1995.00430070117013 7695464
23. Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Nerurkar J, Wade WE, Martin BC, Pharmacotherapy 2002 22 8 990 1000 10.1592/phco.22.12.990.33609 12173802 (Pubitemid 34831294)
24. R Development Core Team, R: A language and environment for statistical computing R Foundation for Statistical Computing, Vienna, Austria 2010
25. Johnson & Johnson Pharmaceutical Research & Development LLC, Advisory Committee Briefing Book; Rivaroxaban for the Prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Patients Undergoing Hip or Knee Replacement Surgery, JNJ-39039039 (BAY 59-7939, rivaroxaban) 19422273
26. Estimated annual costs of prophylaxis and treatment of venous thromboembolic events associated with major orthopedic surgery in France. Tilleul P, LaFuma A, Colin X, Ozier Y, Clin Appl Thromb Hemost 2006 12 4 473 484 10.1177/1076029606293435 17000893 (Pubitemid 44359246)
27. A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma. Lynd LD, Goeree R, Crowther MA, O'Brien BJ, Can J Clin Pharmacol 2007 14 2 215 226 18000316
28. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting. McCullagh L, Tilson L, Walsh C, Barry M, Pharmacoeconomics 2009 27 10 829 846 10.2165/11313800-000000000-00000 19803538
29. GmbH RLS, Rote Liste Arzneimittelverzeichnis für Deutschland, Frankfurt/Main 2010
30. Kassenärztliche Bundesvereinigung, Einheitlicher Bewertungsmaßstab für ärztliche Leistungen 2011 http://www.kbv.de/ebm2011/EBMGesamt.htm 23175236
31. WebGrouper Münster 2010 http://drg.uni-muenster.de/index.php?option= com-webgrouper&view=webgrouper&Itemid=26 23336075
32. Briggs A, Claxton K, Sculpher M, Decision Modelling for Health Economic Evaluation Oxford University Press, Oxford 2006
33. Uncertainty assessment of input parameters for economic evaluation: Gauss's error propagation, an alternative to established methods. Stollenwerk B, Stock S, Siebert U, Lauterbach KW, Holle R, Med Decis Making 2010 30 3 304 313 10.1177/0272989X09347015 19815659
34. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada. Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H, Thromb Haemost 2010 104 4 760 770 10.1160/TH10-01-0071 20806107
35. Bitzer EM, Grobe TG, Neusser S, Schneider A, Dörning H, Schwartz FW, BARMER GEK Report Krankenhaus 2010 Asgard-Verlag, St. Augustin 2010
36. Hakkaart-van Roijen L: Comparing methodologies for the cost estimation of hospital services. Tan SS, Rutten FF, van Ineveld BM, Redekop WK, Eur J Health Econ 2009 10 1 39 45 10.1007/s10198-008-0101-x 18340472
37. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Baglin T, Luddington R, Brown K, Baglin C, Lancet 2003 362 9383 523 526 10.1016/S0140-6736(03)14111-6 12932383 (Pubitemid 36976716)
38. Incidence of post-thrombotic syndrome in patients with previous pulmonary embolism. Bova C, Rossi V, Ricchio R, Greco A, Bloise A, Daniele F, Greco F, Noto A, A retrospective cohort study. Thromb Haemost 2004 92 5 993 996 (Pubitemid 39545521)
39. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Ginsberg JS, Turkstra F, Buller HR, MacKinnon B, Magier D, Hirsh J, Arch Intern Med 2000 160 5 669 672 10.1001/archinte.160.5.669 10724052 (Pubitemid 30140416)
40. Statistisches Bundesamt: Gesundheit. Fallpauschalenbezogene Krankenhausstatistik (DRG-Statistik) Operationen und Prozeduren der vollstationären Patientinnen und Patienten in Krankenhäusern- Ausführliche Darstellung Destatis, Wiesbaden 2011
41. IQWiG: General Methods. Version 4.0 Institute for Quality and Efficiency in Health Care, Cologne 2011
42. Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey. Rogers BA, Phillips S, Foote J, Drabu KJ, Ann R Coll Surg Engl 2010 92 8 668 672 10.1308/003588410X12699663904952 20615303